Our team combines expertise in neuroscience, human genetics, psychiatry, deep learning, nanotechnology engineering, and business to build biological tools that bring greater precision to mental health care.
Julien is a neuroscientist and entrepreneur. As Founder and Chief Executive Officer of OneCare Biotechnologies, he leads the development of the company's multi-omics blood-based diagnostics for psychiatry, overseeing scientific strategy, intellectual property, fundraising, and partnerships. His work combines neuroscience, biomarker discovery, and translational medicine with a drive to bring objective tools to mental health care. Recognized through multiple innovation and research awards, Julien believes precision medicine can transform psychiatric diagnosis and treatment. Outside of work, he enjoys reading and meditation.
Madline, Ph.D., is a molecular biologist, entrepreneur, and postdoctoral researcher at the Université de Montréal. She previously co-founded SensÈn, where she led the development of a graphene biosensor platform for precision medicine. Following the integration of SensÈn into OneCare, she now serves as Vice-President and Chief Product Officer, leading the development of the company's graphene biosensor platform while overseeing scientific strategy, partnerships, fundraising, operations, and commercialization. Passionate about translating breakthrough research into real-world healthcare solutions, Madline enjoys building multidisciplinary teams and has been recognized with several innovation and entrepreneurship awards. Outside of work, she enjoys running, practicing martial arts, and taking on new challenges.
Aiken is a technology entrepreneur and researcher with a background in engineering and clinical sciences. As Chief Technology Officer at OneCare Biotechnologies, he drives technical innovation, software development, and the integration of digital health solutions to improve healthcare accessibility. His multidisciplinary expertise bridges computer science, control engineering, and laboratory medicine, enabling him to build scalable platforms for complex health-tech challenges. Beyond engineering, Aiken explores emerging tech, digital healthcare trends, and multi-disciplinary systems.
Murielle is a molecular biologist, entrepreneur, and operations leader with over 15 years of experience spanning biomedical research, clinical development, and biotech innovation. As Chief Operating Officer at OneCare Biotechnologies, she translates scientific vision into scalable operational strategies driving next-generation diagnostic technologies. Murielle holds a Ph.D. in Human Genetics from McGill University, an M.Sc. from UQAM, and a B.Sc. from Georgia State University. She has led multidisciplinary teams, managed multimillion-dollar programs, and published peer-reviewed research. Outside of work, Murielle enjoys food, travel, and reading.
Daniel is the Chief Business Officer of OneCare Biotechnologies. He holds a Bachelor of Commerce with Distinction from McGill University, majoring in Finance, and has studied International Business to earn a Master's from HEC Montréal. At OneCare, he leads investor relations, grant writing, and strategic partnerships, working to bring the company's vision from the lab to the market. Before OneCare, he was a Financial Analyst at the Canadian Space Agency. Daniel believes the best businesses solve problems that genuinely matter. When he's not building OneCare, you'll find him deep in a good book or rolling dice at a Dungeons and Dragons table.
We're building a network of clinical, scientific, and industry advisors to guide OneCare's growth. Seats are opening soon.
Alain is a physician-scientist and one of Canada's most influential voices in health research policy. He holds an M.D. and a Ph.D., and served as President of the Canadian Institutes of Health Research (CIHR), where he helped shape national priorities for biomedical and clinical research and championed the translation of scientific discovery into real patient impact. His career spans decades at the leading edge of neuroscience and research governance, giving him a rare vantage point on what it takes to move a diagnostic innovation from the lab to the clinic. At OneCare, Alain lends his deep understanding of the research funding landscape and his instinct for scientific rigor to help guide the company's clinical and regulatory strategy. His counsel is a driving force behind OneCare's credibility in the scientific community.
Emmanuel is a leading academic psychiatrist whose career has been devoted to advancing the science and practice of mental health care. He holds an M.D. and served as Chair of the Department of Psychiatry at the Université de Montréal, where he trained generations of clinicians and led research at the intersection of psychiatry, cognition, and neuroscience. His clinical depth and his standing within the psychiatric community give him a rare, ground-level view of the diagnostic gaps OneCare is built to close. As an advisor, Emmanuel brings clinical credibility and a clear-eyed sense of what psychiatrists actually need from a biomarker-based tool, helping ensure OneCare's technology is built for real-world practice, not just the lab.
Alain holds three postgraduate degrees from the University of Montréal: a Master's in Pharmaceutical Sciences, a Ph.D. in Pharmacology, and a Diploma in Toxicology. Alain spent four decades at AstraZeneca, serving for more than 25 years, as a Medical Advisor across multiple therapeutic areas, including neuroscience (stroke, pain, psychiatry), rheumatology, immunology, and respiratory diseases. He is the author or co-author of more than 65 scientific publications, abstracts, and posters, with work appearing in leading journals such as Biological Psychiatry, Journal of Clinical Psychiatry, and Journal of Psychopharmacology. Drawing on four decades of experience at AstraZeneca, fifteen years with the Faculty of Medicine at the Université de Montréal, and extensive service on cross-functional advisory boards, Alain brings a uniquely valuable scientific, clinical, and strategic perspective to OneCare Biotechnologies.
